Latest Financial Performance News

Centuria Industrial REIT has reported a remarkable 176% increase in net profit for the year ended June 2025, alongside a 25% rise in revenue and consistent quarterly distributions.

Charter Hall Long WALE REIT reported stable FY25 financials with a $5.5 billion portfolio and 99.9% occupancy, maintaining strong income security. The REIT projects modest growth in FY26 with a 6.1% distribution yield.

Charter Hall Long WALE REIT reported steady FY25 earnings with strong occupancy and a strategic shift toward government-leased assets, setting the stage for growth in FY26.

BWP Group reported a strong $265.6 million net profit for FY2025, driven by property valuation gains and rental growth, while completing a major internalisation and lease reset transaction with Wesfarmers.

REA Group Ltd reported a robust FY25 with 15% revenue growth to $1.673 billion and a 23% rise in net profit, driven by strong Australian market performance and strategic AI investments. The company also advanced its India operations, focusing on Housing.com amid PropTiger divestment plans.

REA Group has reported a robust FY25 with strong revenue and profit growth, underpinned by solid Australian market performance and strategic moves in India. The company also announced a leadership transition amid optimistic FY26 guidance.

REA Group Ltd has reported robust FY25 results with a 15% increase in revenue and a 23% rise in core net profit, alongside a 31% lift in dividends. The company also announced the retirement of CEO Owen Wilson after a decade at the helm.

Pinnacle Investment Management Group delivered a robust FY2025 with a 49% rise in net profit and a 63% jump in funds under management, driven by strategic international growth and strong affiliate performance.

Pinnacle Investment Management Group Limited has delivered a robust financial performance for FY2025, with revenues and profits soaring and dividends increasing, signaling strong momentum in the asset management sector.

Coventry Group’s FY25 results reveal a sharp EBITDA decline amid ERP disruptions and soft markets, prompting a major cost reduction drive for FY26.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.